Antiplatelet Therapy and Secondary Prevention

Learning Objectives

Data from PLATO, clopidogrel arm; primary efficacy endpoint = CV Death, MI, Stroke

REACH Registry CV Death/MI/stroke or Hospitalization for Atherothrombotic Events

Landmark Analyses Acute vs Chronic Trials

The Sweet Spot for Anticoagulation

Antiplatelet Therapy in ACS Management

Secondary Prevention in CAD Patients

Greater Efficacy of Ticagrelor or Prasugrel vs Clopidogrel

Clinical Benefit of Long-Term Antiplatelet Treatment

Patient #1 3 Months Post-MI

Patient #1: Evaluation at 6 Months Factors to Consider

On-going Risk Assessment Risk Categories

DAPT Trial 12 or 30 Months of Dual Antiplatelet Therapy

Patient #2 85-Year-Old, Frail, Woman

Vulnerable Patient vs Vulnerable Plaque Treatment Approaches

TRACER Vorapaxar for the Treatment of ACS (NSTEMI)

ADAPTABLE Low- vs Regular-strength Daily Dose of Aspirin in Patients With Known ASCVD

TWILIGHT Ticagrelor +/- Aspirin in High-Risk Patients After Coronary Intervention

GLOBAL LEADERS Ticagrelor vs Standard Dual Antiplatelet Therapy

Patient #3 On Dual Antiplatelet Therapy Needing Elective Procedure

Patient #4 Presenting With Recurrent NSTE ACS

PLATO Ticagrelor Efficacy in Patients Previously Treated With Clopidogrel

ACC/AHA Secondary Prevention Guidelines

Future Directions/Knowledge Gap

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)